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ABSTRACT 
Introduction: Although cervical cancer can be prevented through known interventions it still 
remains a major cause of mortality in developing countries. Currently in South Africa there is 
little literature on cervical cancer radiotherapy treatment and its prognostic factors. 
Knowledge of prognostic factors helps in understanding the determinants of a disease better 
and optimize treatment strategies. The aim of this study was to determine overall survival rate 
and to investigate potential prognostic factors for cervical cancer in patients who underwent 
radiotherapy during the period of 1 January 2004 to 31 December 2006 at the Division of 
Radiation Oncology, Charlotte Maxeke Johannesburg Academic Hospital.  
Methods: This was a retrospective cohort study of 900 patients who were treated with 
radiotherapy between 1 January 2004 and 31 December 2006. Patient and treatment related 
data was obtained from the hospital treatment records. Follow-up was then censored as of 31
st
 
of December 2008. Subjects of this study had either mono-therapy or a combination of 
therapies: external beam radiotherapy, brachytherapy and chemotherapy. A Cox regression 
model was fitted to determine the prognostic and predictive factors of cervical cancer.  
Kaplan Meier methods were used to establish the effect of different socio-demographic and 
clinic-pathological factors on overall survival. The overall two year survival was also 
determined.  
Results: At 2 years post-treatment for each individual patient, 26 out of 900 patients had 
died, 281 were still alive and 593 lost to follow up leaving 307 patients available for analysis.  
The overall 2 year mortality rate was 45 per 1000 person years and highest in the period of 0-
6 months.  In the final model, completion of brachytherapy remained a significant predictor 
of survival (HR=0.04, 95% CI: 0.01-0.11, p<0.001) after adjusting for all other factors.  
Furthermore, HIV status was the only significant prognostic factor (HR=3.23, 95% CI: 1.04-
 v 
 
10, p=0.042). Patients who had brachytherapy treatment prescribed and completed the 
prescription were 96% less likely to die compared to those who didn’t complete it at any 
point in time, after adjusting for age and HIV status.  Patients who were HIV positive were 
approximately three times more likely to die as compared to HIV negative patients at any 
point in time after adjusting for age and completed brachytherapy.  The overall 2-year 
survival rate was 92% for this group of patients.  
Conclusion: Completion of the brachytherapy prescription was a significant predictor of 
treatment outcome, while the patient’s HIV status was also a significant prognostic factor for 
treatment. Patients who were HIV positive were three-times more likely to die compared to 
HIV negative patients. The overall 2-year survival rate was 92%, however, these results need 
to be interpreted with caution due to the large loss to follow-up in this patient population. 
Prospective clinical trials are recommended in the future to confirm the validity of the 
findings of this work in a representative patient population. In addition this work puts 
forward some suggestions to optimize treatment of cervical cancer patients in typical 
university teaching public health centres in South Africa. 
KEY WORDS: prognostic factors, predictors, cervical cancer, overall survival 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 What is Cervical Cancer? 
The cervix is the lower portion of the uterus that connects the upper vagina to the uterus [1]. 
It is cylindrical or conical in shape and it protrudes through the upper anterior vaginal wall.  
The cervix allows flow of menstrual blood from the uterus into the vagina and directs sperms 
into the uterus. This structure or organ can sometimes be diseased with cancer. Cervical 
cancer is a disease which affects the cervix in the female reproductive system where 
malignant (cancer) cells can form in the tissues of the cervix [1].   This is a slow growing 
cancer which starts as a precancerous condition called dysplasia and its symptoms are thus 
not always immediately evident [2][3].  This condition can develop into cervical cancer after 
several years [3]. Cervical cancer can be detected or diagnosed through a regular Pap smear 
test, a procedure in which cells are scraped from the cervix and looked at under a microscope 
[2][4]. A persistent infection with human papillomavirus (HPV) of certain subtypes is a 
necessary condition which leads to the development of most cases of cervical cancer [5][3].  
 
Cervical cancer is the third most common gynaecological malignancy after ovarian and 
uterine corpus cancers. More than 90% of cervical squamous cell cancers contain DNA 
evidence of human papillomavirus (HPV). This virus is acquired through sexual activity [6]. 
HPV is a common sexually transmitted infection (STI) in South Africa and worldwide thus 
anyone who is sexually active is at risk of being exposed to HPV [7]. In 2004, it was 
estimated that about 6 800 new infections and 3 700 deaths from cervical cancer were caused 
by HPV every year in South Africa [8].  Although, studies have shown that the development 
and inclusion of an HPV vaccine into the national screening programme would decrease HPV 
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infections which would in turn reduce HPV related cancers, studies published in 2004 
showed that the vaccine was still not provided at South African government clinics although 
available in the private sector [9]. In November 2011, the Global Access to Vaccines 
Initiative (GAVI) announced the decision to support HPV vaccines in the world’s poorest 
countries even though South Africa as a middle-income country did not qualify for access to 
the vaccine by GAVI [10]. Recently in South Africa the health ministry announced that from 
February 2014 a pilot programme will be launched whereby the HPV vaccine will be 
administered to girls aged between 9 and 12 at some schools [11]. Currently due to the poor 
health infrastructure and relatively high costs of the vaccine it remains out of reach for most 
members of the public.  
 
In general as people become more economically viable they will live longer and thus be more 
prone to cancer. Fortunately cervical cancer is both a preventable and curable disease, 
however it still poses a serious health problem in the developing world [5][7]. In developing 
countries cervical cancer is still unnecessarily causing mortality [12].  This unnecessary 
mortality in developing countries is largely due to a lack of disease awareness programs, lack 
of screening in order to detect precancerous and early stage cervical cancer, lack of clinical 
equipment, limited staff training and HIV infection.  Analysis of worldwide cervical cancer 
mortality rates will reveal a lower rate however a targeted analysis of data from developing 
countries shows that both the mortality and incidence rates are very high [12]. The critical 
factor in the fight against this disease is early detection and diagnosis given the fact that in its 
early stages the cancer is curable.  
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1.2  Signs and Symptoms of Cervical Cancer       
In its early stages, the symptoms for cervical cancer are not readily noticeable to the patient. 
However in advanced stages the affected woman is likely to have the following symptoms: 
 Vaginal bleeding 
 Bleeding after sexual intercourse 
 Heavy and longer menstrual periods 
 Pelvic pains 
 Post –menopause bleeding 
 Pain during sexual intercourse 
 Vaginal smelling discharge 
 Pain during urination 
 Loss of appetite and weight loss 
 Changes to bowel and bladder habits 
In most cases vaginal bleeding is the most noticeable symptom of cervical cancer [3]. 
 
1.3  Risk Factors of Cervical Cancer        
Prevention and therapy interventions measures to a disease are likely to succeed if the risk 
factors are known. Below we look in detail at the various risk factors for cervical cancer. 
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Human Papillomavirus (HPV) 
HPV is a sexually transmitted disease that has been proven to be necessary condition for 
cervical cancer. Approximately 100% of all cervical cancer cases are caused by HPV [5]. 
There are different types of HPV and not all of them cause cervical cancer. In general, HPV 
is classified into two categories according to their risk of causing cervical cancer: high risk 
type and low risk type. The high risk type HPV causes cervical cancer while the low risk type 
such as type 6 and 11 causes genital warts[5] [14]. There are 15 HPV types in the high risk 
category and 12 HPV types in the low risk category. In a study by Denny et al it was showed 
that HPV types 16, 18, 45 and 35 were the most common HPV types in sub-Saharan African 
women with invasive cervical cancer and HPV infections were more common in HIV-
positive women [14]. 
Age 
Young age at the first full term pregnancy has been shown to increase the risk of cervical 
cancer.  In particular women who were younger than 17 years of age at the first full term 
pregnancy had 2 times more risk of developing cervical cancer at a later stage in life as 
compared to those who had their first above age 25 [15]. In South Africa, according to the 
NCR 2005 women between the age of 40-59 years were more prone to cervical cancer [2].  
Risky Sexual Behaviour 
The risk factors for cervical cancer closely resemble those of sexually transmitted diseases, 
some of the risk factors are: first coitus at a young age, multiple sexual partners, history of 
other sexually transmitted diseases [16].  Given that HPV which is a sexually transmitted 
disease is the most prominent cause of cervical cancer, it follows that sexual behaviour is a 
huge factor in causing cervical cancer. A strong association has been observed between 
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Chlamydia trachomatis with cervical cancer OR = 5.0 (95% CI 1.6 – 15.7) after adjustment 
for smoking and other STIs.  Women with multiple sexual partners have been shown to be 
more prone to cervical cancer than the control group. In women with only one lifetime sexual 
partner, the sexual behavior of the male partner has a substantial role in the development of 
cervical carcinogenesis [17]. In Tunisia a very low rate of incidence was attributed to the late 
age of first sexual activity.    
High Parity 
Studies have proved an association between parity and cervical cancer. Women who had 
more births were more prone to cervical cancer than those who had only 1 or 2 births, OR 
=2.6 (95% CI 1.6 – 4.3), 3 – 4 births, OR = 5.7 (95% CI 3.0 – 11.1), 5 -6 births and for 
greater than 7 births, OR = 5.7 (95% CI 2.4 -13.3) [18]. Women who had 3 or more, full term 
pregnancies also were at increased risk of developing cervical this might have been due to 
their increased exposure to HPV through unprotected intercourse [15].  
Smoking 
Tobacco smoking increases the risk of cervical cancer incidence in women. Researchers have 
found tobacco by products in the cervical mucus of women who smoke and this is believed to 
cause damage to the DNA of cervix cells as such increasing the development of cervical 
cancer [15]. Berrinton et al proved a significant increased risk of squamous cell carcinoma 
OR = 1.47 (95%CI 1.15-1.88) but not of adenocarcinoma OR = 0.82(95%CI 0.60-1.11) [19] 
Oral Contraceptives 
Women who use oral contraceptives for 5 years or more have been shown to have a higher 
risk of cervical cancer but the risk goes back down again after the oral contraceptives are 
stopped [15]. 
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Socio-economic Status 
Low socio-economic status and education are risk factors in cervical cancer, in the sense that 
such people are less likely to take up to cervical cancer screening. Uneducated, poor women 
are also less likely to access information about cervical cancer and cervical cancer screening. 
In countries where healthcare is not free then most likely the poor will only present with 
advanced tumours as they fail to go for screening. 
   
1.4  International Cervical Cancer Screening Recommendations  
Much of the success of cervical cancer management worldwide has not only been due to the 
efficiency of the treatment modalities but also due to the success of mass screening [20][21]. 
Despite the clear benefits of screening in the fight against cervical cancer, it is not readily 
accessible in African countries because of lack of resources. In comparison to the primary 
healthcare demands, HIV pandemic and other urgent health care needs, African countries 
cannot afford to fund cervical cancer screening and its associated activities. 
 
There are conflicting recommendations on the frequency of screening; the American Cancer 
Society has recommended that asymptomatic women 20 years of age or older or sexually 
active have two initial consecutive annual Pap smears and thereafter have at least triennial 
Pap smears. However the American College of Obstetricians and Gynaecologists strongly 
advocates for women to undergo Pap smears on an annual basis.  
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A significant number of women still remain unscreened despite the benefits of screening. In 
the United States 50% of the women with newly diagnosed invasive cervical cancer have 
never had a Pap smear, another 10% have not had a Pap smear in 5 years [22]. Interestingly, 
based on data from the United States, women who are underscreened tend to be 
postmenopausal, uninsured, ethnic minority, elderly black and poor in rural areas. 
 
1.5 Cervical Cancer Staging    
Cancer staging gives a description of the size and spread of the disease. This is done at the 
time of diagnosis and sometimes also before the treatment where there has been a long gap 
between diagnosis and treatment, as this can change depending on how quickly the cancer is 
growing or spreading. Staging describes the extent or spread of the disease at the time of 
diagnosis. This staging also helps in determining the choice of treatment and it is based on 
the primary tumour’s size and location and whether it has spread to other areas of the body 
[23].  There are different staging systems such as TNM are used to classify tumours 
according to the size and extent of the primary tumour (T), absence or presence of regional 
lymph node involvement (N) and absence and presence of distant metastases (M). Once the 
T, N, and M are determined, stages are assigned from I, II, III, or IV with stage I being early 
stage and stage IV being advanced [23]. Figure 2.5 below shows a summary of the 
description of cervical cancer staging according to FIGO [24].  
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Table 1.1: The revised FIGO staging for carcinoma of the cervix [24]. 
 
The International Federation of Gynaecology and Oncology (FIGO) staging classification for 
cervical cancer is clinically staged, thus failing to officially incorporate modern radiologic 
methods of staging, including magnetic resonance imaging (MRI), computed tomography 
(CT) and positron emission tomography (PET). Furthermore the FIGO staging system fails to 
consider important prognostic variables such as lymph node involvement and to some extent 
tumor size (tumor size is only recognized for Stage 1B1, IB2 and stage 2 tumors) [25]. 
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1.6 Treatment Options for Cervical Cancer 
There is a variety of treatment options for patients with cervical cancer, some of them being 
surgery, radiation therapy, chemotherapy, therapeutic conization, laser therapy and 
cryotherapy [26][27][28]. Presently in South Africa the most common treatment modalities of 
choice are surgery, chemotherapy and radiation therapy. Surgery in the form of hysterectomy 
involves removal of the uterus. Chemotherapy is the use of drugs to stop the growth of cancer 
cells, either by killing the cells or by stopping them from dividing.  These drugs can either be 
given by mouth, injected into a vein or muscle, or placed directly into a spinal column, organ 
or cavity. The method used for the administration of chemotherapy depends on the type and 
the stage of the cancer. Radiation therapy uses high-energy x-rays or other types of ionizing 
radiation to kill cancer cells or keep them from growing [29]. There are two types of radiation 
therapy which are external beam radiation therapy uses a machine outside the body to send 
radiation toward the cancer and brachytherapy also known as short distance therapy which 
uses a radioactive sources sealed in needles, seeds, wires, or catheters that are placed directly 
into or near the cancer. The way the radiation therapy is given also depends on the type and 
stage of the cancer being treated [29].  
 
Surgery is generally the preferred option in young women with small squamous carcinoma to 
avoid radiation-related ovarian failure and minimize the risk of sexual dysfunction. 
Aggressive radiation therapy, involving a combination of external beam radiotherapy and 
brachytherapy, concurrent with cisplatin-based chemotherapy is now the standard of care in 
treating bulky and loco-regionally advanced tumors [30]. Figure below gives a summary of 
the treatment options for different stages in cervical cancer.     
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Figure 1.1: Treatment options for the different stages in cervical cancer [30]. 
 
1.7 Epidemiology - Worldwide 
Worldwide cervical cancer is the fourth most common malignancy in women [12]. The wide 
range in the incidence rates across the globe potentially reflects the variation in 
epidemiologic risk factors that is compounded by lack of screening resources in poor 
communities or countries.  Figure 1.2 below shows the worlds’ age standardized incidence 
and mortality rates estimates as at 2012 [12]. 
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Figure 1.2: Estimates of world cervical cancer age-standerdized incidence and mortality 
rates in 2012 [12]. 
The above graphs shows that cervical cancer incidence rates were lowest in Western Asia and 
highest in Eastern Africa [12]. 
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A full representation of the incidence rates worldwide is given in Figure 1.3. Below is a 
representation of the cervical cancer incidence rates in the world as of the year 2012. There is 
a wide variation in the incidence rates across the world, with rates ranging from 5.5 per 100 
000 in Australia/New Zealand and 4.4 per 100 000 in Western Asia to 42.7 per 100 000 in 
Eastern Africa in 2012 [12].   
 
 
Figure 1.3: Estimated cervical cancer incidence worldwide in 2012 [12]. 
The trend in most countries all over the world shows that there is a general decline in cancer 
incidence rates. Below are trend graphs for different countries showing the incidence rates 
[12]. 
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Figure 1.4: Trends in incidence of cervical cancer in a few selected countries: age 
standardized rate per 100 000 in 2012[12]. 
India, despite still having high incidence rates has managed to reduce these rates over the last 
decade. The Indian experience can be compared to South Africa as their healthcare 
challenges are similar. 
 
 In 2012 there were 266 000 deaths from cervical cancer worldwide, which accounted for 
7.5% of the total cancer deaths in women. Of these deaths, 87% occurred in developing 
countries. Below is a world map showing mortality rates world-wide [12].  
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Figure 1.5: Age standardized cervical cancer mortality rates per 100 000 worldwide in 2012 
[12]. 
As the case with incidence rates there is a wide variation between the mortality rates across 
the world. The mortality rates are generally high in developing countries, for example in 2012 
the mortality rates ranged from 2 per 100 000 in Western Europe, Western Asia and 
Australia/New Zealand to 27.6 per 100 000 in East Africa [12].  
 
1.8 Epidemiology – South Africa 
Cervical cancer is the fourth most common cancer in women worldwide [12]. In 2012, about 
85 % of the cancers occurred in developing countries, representing 12% of all female cancers 
[12]. According to South African statistics, cervical cancer is the second most common 
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female cancer in South Africa [7]. Figure 1.6 below shows the incidence for cervical cancer 
compared to other cancers among South African women of all ages [5].  
 
Figure 1.6: Annual crude incidence rate per 100 000 in South African women of all ages, 
2014 [5] 
According to the South African National Cancer Registry (2005) the lifetime risk of 
developing cervical cancer is 1 in 39 for all females, 1 in 92 for Asian, 1 in 33 for black, 1 in 
44 for coloured and 1 in 81 for white females [2].  The number of histologically diagnosed 
cervical cancer per age group in South Africa is shown in Table 1.2 below [2] 
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Table 1.2: The number of histologically diagnosed cervical cancer among South African 
women according to age and ethnicity (SA NCR 2005) [2] 
Group Age groups (years) 
 0 – 29 30 – 39 40 – 49 50 – 59 60 – 69 70+ 
All 
Asian 
Black 
Coloured 
White 
 
115 
1 
84 
14 
7 
676 
8 
495 
65 
62 
1158 
17 
840 
105 
127 
1077 
14 
804 
102 
94 
847 
15 
646 
62 
55 
608 
2 
438 
34 
91 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Prognostic Factors  
Determination of prognostic factors helps in predicting the outcome or occurrences of 
diseases in the population and guides use of health care system resources.  This also helps in 
designing public health prevention and intervention measures in order to reduce the 
incidences and severity of these particular diseases based on the results of these studies.   
Prognostic factors of cervical cancer have mostly been studied in the US, Canada, India to 
name a few, below are examples of such studies. A literature search shows an apparent 
scarcity of data from low-to-middle income countries, thus the motivation for this study. 
Below a number of potential prognostic factors for the cervical cancer are discussed. 
 
2.2 Studies from Developed Countries  
Below is a discussion of cervical cancer prognostic factors as determined by studies in first 
world countries.  
Age 
The issue of age as a prognostic factor in cervical cancer has been surrounded with 
controversy with some investigators being of the view that age is not a prognostic factor [31]. 
In addition there has been conflicting conclusions with some studies observing decreased 
survival rates in younger patients while others have findings to the contrary. Dattoli et al. 
observed a decrease in survival rates for patients younger than 35 or 40 years [32]. In 
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contrast, two European studies showed improved treatment outcomes in younger patients 
[33]. In contrast, Kastritis et al observed younger patients (less than 35 years) and older 
patients (above 70 years) to have the worst survival post treatment [34]. A review based on 
American data by Duarte-Franco and Franco concluded that in general patient survival 
decreased with increasing age [35]. Given the different conclusions from different studies the 
proposed study will derive home grown data and thus relevant conclusions to our local 
patient population. 
Human Immunodeficiency Virus (HIV) 
The International Atomic Energy Agency (IAEA) technical document on the role of 
radiotherapy in HIV infected patients recommends that for patients presenting with early 
stage disease and profound immunosuppression, the HIV infection rather than the tumour 
should dictate the prognosis [36]. Conversely for those patients presenting with advanced 
disease but with normal CD4 counts, the prognosis is dominated by the tumour. In the 
developed world, some studies have shown that HIV positive patients are at a higher risk for 
tumor recurrence after treatment and death as a consequence of the malignant process 
[37][38]. 
Tumor Stage 
The clinical stage of the cervical cancer at the time of commencement of treatment has 
proved to have an effect on treatment outcome. Cervical cancer is classified into four stages 
(Stage I to Stage IV), each stage with sub categories; however the tumour size increases from 
Stage I through to Stage IV. Chances of disease control decreases from 95% to 10% for Stage 
I and Stage IV tumours respectively [7][1]. Patients with advanced clinical stage had poor 
prognosis as compared to those with early stage. Hopkins and Morley [39] and two other 
 19 
 
authors also confirmed that the higher the cancer stage the poorer the prognosis in their 
studies [40][35].    
 
The spread of the cancer to nearby lymph nodes has an effect on treatment outcome. For 
example for a Stage IA cancer the 5-year survival rates are 25% to 60% lower in women with 
positive lymph nodes in comparison to those with negative status [35]. Based on 
clinicopathologic review of patients Hopkins and Morley also showed that urethral 
obstruction and renal failure lead to a poor prognosis for patients being treated for cervical 
cancer [39]. A striking recommendation of their research was that for advanced Stage IVa 
there is a chance of significant survival. This is particularly encouraging in the South African 
set-up where patients normally present with advanced disease.  
Treatment Modalities 
The treatment of cervical cancer is normally achieved by use of multi-therapy strategies, 
which is through radiation therapy, surgery and chemotherapy. It has been postulated that a 
combination of chemotherapy and radiation leads to superior treatment outcomes in 
comparison the use of radiation therapy only. However, the study by Duval revealed that 
there was a doubtful survival benefit when postoperative external beam radiotherapy is used 
alone as compared to being used in conjunction with chemotherapy [41]. In a study published 
in 2000 by William et al based on data collected from 1991 to 1996 post-operative radiation 
therapy alone and radiation therapy in combination with chemotherapy as a prescribed 
treatment was investigated with regard to  improved  overall survival of early stage cervical 
cancer patients [42].  This study showed a 71% overall survival in patients treated with 
radiation therapy only and 81% overall survival in those treated with both chemotherapy and 
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radiation therapy.  There is however, conflicting findings from clinical researchers on the 
effect of chemotherapy drugs given concurrently with radiation on treatment outcomes 
[42][43][44].   
Treatment Time/Duration 
Time is an important parameter in the management of cancer, i.e. initiation of treatment and 
duration of treatment. Cancer cells are in a state of perpetual growth and multiplication so the 
timing of the intervention procedure is critical. If the intervention is done late in the life of the 
cancer then it is difficult to control the disease as most likely it would have metastasized. On 
the other hand if the intervention occurs over a prolonged period it won’t be able to suppress 
or catch-up with the tumour growth, bearing in mind that an intervention naturally triggers 
repopulation of the tumour. Duval showed in his literature review that an increase in the 
overall treatment time due to treatment interruptions (for example lack of adherence to 
treatment, machine breakdown), reduced the biological effect and hence the probability of 
cure [41].  In radiation therapy, it has been estimated that for every one day increase in total 
treatment time, the loss in biological effect is equivalent to a 0.6 Gy dose reduction [45]. In 
addition, Fyles et al studied the effect of treatment time on disease/pelvic local control and 
also found that there was 1% loss of control per day of treatment prolonged beyond 30 days.  
This effect was even more in stages III and IV as compared to stages I and II [46].  These 
effects remained significant after accounting for other factors thought to may have had 
influence in the local control such as, treatment complications and many more.  In their 
conclusion unnecessary delays especially in stage III and IV patients should therefore be 
avoided.  
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2.3 Studies from Developing Countries 
As has been pointed elsewhere in this research report, published data on cervical cancer from 
low-to-middle income countries is sparse. Below is a review of the few data from African 
studies and other developing countries. Rogo et al carried out a study to describe the 
prevalence and distribution of cervical cancer in sub-Saharan Africa, using Kenyan data [47]. 
All the patients were staged according to the FIGO clinical staging and allocated to either 
receive radical hysterectomy and/or radiotherapy for early stages and radiotherapy only for 
those in late stages. The results showed no correlation between prevalence and ethnic 
patterns, geographical and socioeconomic status.   Also showed a large number of late stages 
for younger age groups in contrast to the data from Geetha [40]. Thus confirming that in 
developing countries the disease is mostly detected at its late stage. Survival rates were 
however shown to be best for patients given combined teletheraphy and brachytherapy which 
contradicts the study by Melahat et al [48]. 
Age 
In a retrospective study by Geetha et al done in India, the effect of the patient’s age as a 
prognostic factor was investigated [40].  Their results showed that the incidence of cervical 
cancer was less in young women below the age of 30 and older women above 70.  In 
addition, the study found that younger patients (less than or equal to 30 years) had longer post 
treatment survival as well as older patients above age 70.  
HIV  
The scourge of HIV AIDS has affected every facet of disease management. Studies done 
around the world have shown that people with HIV have a higher risk of some types of 
cancers than uninfected people due to a weakened immune system caused by HIV 
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[49][50][51][52][53]. Cancers like cervical cancer, non-Hodgkin lymphoma and Kaposi 
sarcoma have been labeled as “AIDS-defining conditions” meaning that they signify AIDS in 
HIV infected people. HIV infected women are at a high risk of cervical intraepithelial 
neoplasia (CIN), however, there is no demonstration of an excess risk of invasive cervical 
cancer [54]. The IAEA points out the need to establish the effect of radical radiotherapy on 
HIV positive women with cervical cancer. In addition they suggest that such data be from 
countries with high prevalence of both HIV and cervical cancer of which South Africa suits 
the criteria. 
In agreement with other studies done in developed countries, Campbell et al have studied 
HIV positive patients with carcinoma of uterine cervix and they concluded that HIV positive 
patients had more advanced tumors and a shorter remission period [55]. Kigula-Mugambe 
and Kavuma found that, the survival probabilities for HIV positive patients were less than 
that of HIV negative ones, and at 4 years the survival probability had dropped to 0% and 46% 
respectively [56]. This was in agreement with another study by Maiman et al which showed 
that HIV positive patients had a poorer response to treatment than their HIV negative 
counterparts [57].  In addition both studies showed that HIV positive patients presented with 
more advanced stage disease and their survival probabilities had a rapid fall off.  This shows 
the importance of screening programs in high risk groups such as HIV positive patients which 
can lead to an increase in early disease detection and better treatment outcomes [56][57].   
Tumour Stage 
A Thai study demonstrated that cancer stage as a prognostic factor was statistically 
significant (p-value < 0.001) in survival of patients. In this study Stage III patients had a 
1.65-fold mortality risk compared to Stage I patients (95% CI 1.05 – 2.59) [58].  This is in 
agreement with studies done in developed countries which proved that, patients with 
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advanced clinical stage had poor prognosis as compared to those with early stage. In a study 
by Pesee et al it was established that patients with tumours less than 2 cm had superior 5 year 
overall survival compared to those with tumours greater than 2 cm [59].    
Timing of Treatment Commencement 
A study conducted by Pomros and co-investigators proved that the timing of administration 
of brachytherapy was a significant (p-value < 0.001) prognostic factor in cancer of the cervix.  
This study showed that patients who had their brachytherapy administered in over 28 days 
since the start of external beam therapy had a 2.28-fold mortality risk compared to those who 
had brachytherapy within a day of external beam therapy (95% CI =1.40 – 2.44) [58].    
 
2.4 Status of screening in South Africa 
A persistent infection of some oncogenic strains of HPV has been proven to be a necessary 
condition for the development of most cases of cervical cancer [5]. There are a number of 
HPV subtypes, namely, types 16, 18, 31, 33, 35 and 45 of which types 16 and 18 present the 
highest risk of inducing cervical cancer globally [60]. However availability of vaccines 
against the oncogenic strains of HPV provides hope in the fight against cervical cancer in 
South Africa. This hope is premised on the idea that a lower HPV infection rate should in 
turn drastically reduce the incidence rates of cervical cancer. Success of the vaccination 
programs is pinned on aggressive awareness and screening campaigns. 
In 2001, South Africa launched the national cervical cancer screening programme, which 
offered women aged 30 years and above 3 free Pap smears per lifetime every 10 years [61].  
The program’s goal was to screen about 70% of women attending public sector services, over 
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the age of 30 years within 10 years, after the implementation of the policy.  A study 
conducted by Moodley et al 2006, showed difficulties with implementation of the cervical 
cancer screening programme in South Africa [61]. Although in South Africa there has been 
implementation of such policies, there has been a lot of debate as to what is the most suitable 
policy with regards to the age at which the smear should be done and time interval between 
smears as well as how often for HIV positive women [62][63].  The jury is still out on 
whether the programmes have been effective in reducing the incidence of invasive cancer in 
South Africa. In a paper by Hoffman et al, it was shown that screening had been done mostly 
for young age groups who are relatively at low risk [62].  This is because the services are 
performed when women attend public health services for family planning and antenatal 
clinics and the majority of these women would be below 30 years of age.  The study was 
done to investigate the effect of Pap smear screening on the incidence of invasive cervical 
cancer among women below age 65 years in the Western Cape, South Africa where screening 
is said to be limited.  The results confirmed that there was a decrease in the incidence of 
invasive disease due to screening.  There was 57% reduction in coloured women and 37% in 
black African women.  The reduction in the risk was greater with frequent screening 
regardless of the acknowledged limitations in the quality and quantity of the screening 
programme [62].  It therefore stands to reason that further risk reduction is expected with 
improved screening performance standards and widespread use of Pap smear tests targeted to 
the appropriate age groups at risk. 
Hoque et al conducted a study to assess the level of knowledge of the risk factors of and 
attitude towards cervical cancer among female university students in South Africa, through a 
self-administered and anonymous questionnaire.  The results revealed that a large number of 
students were sexually active, had more than one partner and had previously contracted 
STDs, had long use of contraceptives and smoked [64].  Risky sexual behaviour leads to an 
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increase in HPV prevalence which would in turn increase the risk of cervical cancer.  Most of 
these students had never heard of Pap smear test, cervical cancer and its risk factors.  Those 
who knew about it did not know it was preventable and that the Pap smear test was used as a 
detection and prevention method for cervical cancer. This shows that a lot of work still has to 
be done to promote health education in order to reduce the spread of preventable health 
conditions. 
 
2.5 Problem Statement 
Research publications on the determination of the prognostic factors of cervical cancer in 
South Africa are scarce.  As a result the treatment protocols used in South Africa are adopted 
from international studies without appropriately taking into consideration local circumstances 
and context. The proposed study will elucidate prognostic factors for treatment of cervical 
cancer with the aim to identify factors which will optimize the treatment protocol at Charlotte 
Maxeke Johannesburg Academic Hospital, South Africa and potentially be relevant to any 
typical developing world clinical setting.  
 
2.6 Justification 
Health systems use valuable resources and personnel as such it is important that the system is 
regularly evaluated and improved in order to use it to its fullest effect.  This can be done by 
examining factors which can help with patient’s prognosis on individual basis, this is 
important for a number of reasons, for example it aids in identifying those patients who are 
most likely to benefit from early detection and treatment. In addition knowledge of 
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prognostic factors helps health workers understand the determinants of a disease better and 
thus encourage and stimulate future research. Furthermore, with knowledge of prognostic 
factors health workers can ably give recommendations and support for the planning of future 
clinical trials, for example, selection of patients, stratification, development of new local 
treatment protocols etc. Current clinical practice in radiation therapy is informed by protocols 
designed in developed countries, which is not a necessarily representative patient population 
and the challenges of the healthcare systems are different. It is therefore important that local 
data is collected and analysed with the aim of developing treatment protocols based on the 
local patient population. In the specific context of this study, it is envisaged that results of this 
study will lead to an optimized radiotherapy strategy informed by statistically significant 
prognostic factors of cervical cancer in a typical South African patient population. 
2.7 Objectives 
The aim of this study is to investigate potential prognostic factors for cervical cancer in 
patients who underwent radiotherapy during the period of 1 January 2004 to 31 December 
2006 at the Division of Radiation Oncology, Charlotte Maxeke Johannesburg Academic 
Hospital, with follow-up visits up to 31 December 2008 post-treatment completion. Some of 
the patients would have in addition to radiotherapy had other forms of therapy, for example 
surgery or chemotherapy. 
The specific objectives of this study are:   
1. To describe socio-demographic characteristics of cancer patients who underwent 
radiotherapy at Charlotte Maxeke Johannesburg Academic Hospital treated during the 
period: 1 January 2004 to 31 December 2006. 
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2. To identify potential prognostic factors for cervical cancer patients undergoing 
radiotherapy.  
3. To determine the 2 year overall survival rate for the same group of patients. 
4. To determine the effect of the tested prognostic factors on overall survival rate. 
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CHAPTER THREE 
METHODS 
 
3.1 Study design   
A retrospective cohort study on cervical cancer patients treated at the Division of Radiation 
Oncology, Charlotte Maxeke Johannesburg Academic Hospital during the period 1 January 
2004 to 31 December 2006 with treatment data available was conducted.  For any study on 
prognostic factors to be statistically sound the patients have to be followed up for a minimum 
period of 5 years. Given this requisite for a fairly long follow-up period, a prospective study 
is not feasible thus a retrospective study has been adopted. 
 
3.2 Study area 
The study was conducted at the Division of Radiation Oncology, Charlotte Maxeke 
Johannesburg Academic Hospital which is a public/government hospital based at 
Johannesburg, Gauteng.  The hospital receives patients from most parts of Gauteng and some 
parts of the North West province. The number of patients with cervical cancer treated in the 
hospital ranges between 500 and 600 yearly.  This hospital’s Radiation Oncology department 
is the largest of the two available public oncology centres thus this is likely to be 
representative of cervical cancer population in the South African public sector.  
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3.3 Study population 
All cervical cancer patients who had undergone radiotherapy treatment at Charlotte Maxeke 
Johannesburg Academic Hospital, during the period 1 January 2004 to 31 December 2006 
were eligible for this study. 
3.4 Inclusion and Exclusion Criteria 
All cervical cancer patients treated during the period of 1 January 2004 to 31 December 2006 
with follow up visits of at least two years post treatment were eligible for the study.  
All cervical cancer patients, who were lost to follow up before cut off date/end of study 
period 31 December 2008 were excluded from the study. 
 
3.5 Sampling and Sample Size 
At the end of the 2 years follow up period post treatment, only 307 patients who had 
complete follow up data were included in the analysis. 
   
3.6 Data collection  
To evaluate all the objectives of the study, a data collection sheet was designed for recording 
the information gathered from the patients’ hospital records.  Information collected included 
patient demographics, clinical history and treatment regime and post treatment follow up 
dates.  From the hard copy data collection sheet the data was manually transferred into the 
software Epi Info Version 3.5.1 database. To avoid transcription errors all the collected raw 
data was verified and validated (cleaned) before analysis.   All the analysis was done with 
STATA Version 12.   
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3.7 Data Collection and Management 
Data was collected from patients’ hospital records, from which various socio-demographic 
characteristics of the patient population were recorded. In addition patient clinical data and 
dosimetry parameters were collected from the patient’s file.  Follow-up information was 
obtained from doctors review/follow up notes in patient’s hospital file (patients see the 
consulting radiation oncologist as follows: weekly while patient is on treatment, every three 
months post treatment during the first year, bi-annual in the second year post treatment and 
thereafter once a year).  Patients who were lost to follow up were dropped from the study. All 
the data collection was exclusively done by the author.   
 
3.8 Definition of terms 
For the purposes of this study the following definitions apply:  
Table 3.1: Definition of terms used in this study. 
Term Definition 
Alive All patients who are alive two years after treatment (living 
with nor without the disease) 
Dead 
All patients who had died or got lost to follow up before 31 
December 2008. 
Age Date of birth to date of diagnosis. 
Treatment duration days Treatment Start Date – Treatment End Date 
Waiting period Date of Diagnosis – Treatment Start Date 
Last follow up date Date last seen alive at the clinic post treatment. 
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3.9 Statistical Analysis Plan 
The statistical analysis plan is described below. 
3.9.1 Descriptive Statistics 
The data was subdivided into demographic characteristics, clinical presentation of the disease 
and treatment history.  The study populations’ demographic characteristics were summarized 
in the tabular form. Continuous variables were summarized and described using their mean 
and standard deviation if their distribution was normal or median and inter-quartile range if 
they were not normally distributed.  Categorical variables were tabulated and described using 
their frequencies and percentages.  The participants were then grouped according to their 
mortality status and the differences between these groups tabulated. To test whether the 
difference was significant a chi squared test was used for all categorical variables. The 
difference was considered significant if the p-value was < 0.2.    
3.9.2 Inferential Statistics 
Inferential statistics was used to determine the impact of the potential prognostic factors on 
treatment outcome in terms of the overall survival of cancer patients on radiotherapy.  
Treatment outcome in terms of patient overall 2 years survival was described using Kaplan 
Meier survival curves.  The influence of different socio-demographic and clinico-
pathological factors was analysed using Kaplan Meier survival curves.  To tests whether the 
difference observed on the survival curves was significant, a log-rank test was done.  The 
difference was considered significant if the p-value was less than 0.2.   
Cox proportional hazard regression model was used to assess the impact of potential 
prognostics factors on the overall survival. The underlying time variable in the counting 
process was   treatment end date with entry time defined as the subject’s date at the end of 
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treatment and exit time as date of last follow up/death, whichever came first.  Factors 
identified in univariate analysis with a p-value ≤ 0.20 were considered as potential candidates 
of the final model and therefore added in the multivariate model.   Factors that were found to 
be significant prognostic factors from previous studies were also included in the multivariate 
analysis. For the final model factors that had a p-value <0.05 in the multivariate model were 
included.  Proportionality assumption, which is one of the main assumptions of Cox 
proportional hazard model was tested for using the Schoenfeld and scaled Schoenfeld 
residual method.  Also the goodness of fit of the model was tested using Cox Snell residuals.   
 
3.10 Ethical Considerations  
To maintain confidentiality and protect patients’ identity, all the participants in the study 
were given a unique identifier and their personal details such as names were removed before 
any data was described and analyzed.  This study was approved by Human Research Ethics 
Committee at the University of the Witwatersrand. 
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CHAPTER FOUR 
RESULTS 
 
This chapter gives a summary of the study results.  The descriptive characteristics of the 
study participants are first reported then the association between mortality and study variables 
are explored and finally the potential prognostic and predictive factors identified. The 
incident rates and cumulative probabilities of mortality were also reported.  
4.1 Descriptive Statistics  
4.1.1 Descriptive statistics of the cohort 
There were 1119 patients treated between the periods of 1 January 2004 – 31 December 2006 
although not all of them met the inclusion criteria. 202 of the 1119 patients didn’t have any 
follow up data and 17 were duplicates and were therefore dropped. A further 593 were lost to 
follow up and dropped, resulting in 307 study participants for the analysis who had complete 
treatment data 2 years post treatment. Table 4.1 below gives a description of the demographic 
characteristics of patients who were enrolled in the study.   
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Table 4.1: Frequency table of demographic characteristics of participants  
Variables Number 
N=307 
Percentage 
% 
Age group:   <30 
                     30-39 
                     40-49 
                     50-59 
                     60-69 
                       70+ 
Missing
*
 
7 
54 
102 
78 
39 
14 
13 
2.3 
17.6 
33.2 
25.4 
12.7 
4.6 
4.2 
Marital Status 
Married 
Single 
Missing
 
 
127 
136 
44 
 
41.4 
44.3 
14.3 
Parity:              0 
                        1-4 
                        5-8 
                        9+ 
Missing
1 
4 
36 
146 
64 
57 
1.3 
11.7 
47.6 
20.8 
18.6 
HIV Status 
Positive 
Negative 
Missing
 
 
71 
231 
5 
 
23.1 
75.2 
1.6 
CD4 Count 
≤ 200 
>200 
Missing 
 
19 
49 
3 
 
26.8 
69.0 
4.2 
Province  
Gauteng  
North West 
 
278 
29 
 
90.6 
9.4 
Alive at 2 Years 
Alive  
Dead 
Lost to follow up 
 
281 
26 
593 
 
31.2 
2.9 
65.9 
 
The average age of participants was 49.1 years (standard deviation 11 years).  The majority 
of women (33%) were between the age of 40 and 49 years and only five percent (5%) were 
above the age of 70.  Forty one percent (41%) of them were married. Twenty three percent 
(23%) of the women were HIV positive; two thirds (69%) had a CD4 count above 200. The 
majority of these women (91%) came from different areas in Gauteng province. At the end of 
                                                             
* Missing: Not documented 
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follow up (2 years), only 3% out of the 307 with known outcome were dead. There was 66% 
loss to follow up at the end of study follow up period. 
 
Furthermore the patient population was stratified according to their clinico-pathology 
characteristics. Table 4.2 below gives a descriptive summary of the clinical presentation of 
the disease of the patients.  
Table 4.2: Descriptive summary of clinical presentation of the disease 
Variables Number 
N=307 
Percentage 
% 
Type of Cancer 
Adeno Carcinoma 
Squamous Cell Carcinoma 
Missing
†
 
 
29 
269 
9 
 
9.5 
87.6 
2.9 
Patient General Condition  
Ecog 0-1 
Ecog 2 
Ecog 3-4 
Missing
 
 
265 
29 
3 
10 
 
86.3 
9.5 
1.0 
3.3 
Cancer Stage at Treatment 
I 
II                   
III  
IV 
 
47 
157 
96 
7 
 
15.3 
51.1 
31.3 
2.3 
 
Squamous cell carcinoma was the leading histological type (88%) followed by adeno 
carcinoma (9%) and the other 3% had missing type.  Eighty six percent of the patients (86%) 
had good general conditions according to their ECOG score. Most patients had stage II (51%) 
and stage III (31%) and only fifteen percent (15%) had early stage I.  
 
                                                             
† Missing: Not documented 
 36 
 
Patients in this study had mono-therapy or multi-therapy, the available therapy options being: 
EBRT, brachytherapy or chemotherapy. Table 4.3 below gives a descriptive summary of the 
treatment modality used.  
Table 4.3: Descriptive summary of treatment modality history 
Variables Number 
N=307 
Percentage 
% 
Treatment Modality 
EBRT
1
 Only                      
EBRT + Brachytherapy 
EBRT+ Brachytherapy+ Chemotherapy 
 
10 
116 
181 
 
 
3.3 
37.8 
59.0 
EBRT Completed 
Yes 
No 
 
273 
34 
 
88.9 
11.1 
Brachytherapy Completed               
Yes 
No                         
Not Prescribed 
 
277 
20 
10 
 
90.2 
6.5 
3.3 
Chemotherapy Prescribed 
Yes 
No 
Missing
2 
 
181 
117 
9 
 
59.0 
38.1 
2.9 
Completed Follow UP 
Yes 
No 
 
281 
26 
 
91.5 
8.5 
Treatment Duration
3
 days group 
≤ 60 days 
>60 days 
 
299 
8 
 
97.4 
2.6 
Waiting Period
4
(Diagnosis-Treat) 
0-6 months 
6-12 months 
12+ months 
Missing
2 
 
225 
52 
17 
13 
 
73.3 
16.9 
5.5 
4.2 
Total Follow Up Completed 
< 6 Months 
6 – 12 months 
12 – 18 months 
18 – 24 months 
 
13 
9 
3 
282 
 
4.2 
2.9 
1.0 
91.9 
1
EBRT: External beam radiotherapy 
2 
Missing: Not documented 
3 
Treatment duration days: Treatment Start Date – Treatment End Date 
4 
Waiting period: Date of Diagnosis – Treatment Start Date 
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Most patients (59%) were treated with a combination of external beam radiotherapy plus 
brachytherapy and chemotherapy, followed by those treated with external beam radiotherapy 
plus brachytherapy only (38%). Only three percent (3%) of the patients were treated with 
external beam radiotherapy only.  Eighty nine percent (89%) of the patients receiving 
external beam radiotherapy completed it while 90% of those prescribed brachytherapy 
completed it. 97% of patients finished the prescribed treatment within 60 days. 92% of the 
patients completed the 2 years follow up period. 
 
4.1.2 Descriptive characteristics and association of the cohort with mortality  
At the end of follow up period (30 December 2008) only 26 patients out of 900 enrolled 
between 1 January 2004 and 31 December 2006, were known to be dead. A total of 593 
became lost to follow up and were dropped.   281 patients were still alive at the end of the 
study period. Table 4.4 shows the descriptive characteristics of patients who died and those 
who were still alive.  The difference between these two groups (Alive/Dead), were then tested 
using Chi-squared test for all categorical variables. In Table 4.4 the percentages in brackets 
represent the proportion in that particular group.  
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Table 4.4: Demographic factors associated with crude mortality
 
Variable Mortality = 0 
(Alive) N=281 
Mortality= 1 
(Dead)  N=26 
p-value
‡
 
Age group:  0-29 
                   30-39 
                   40-49 
                   50-59 
                   60-69 
                     70+ 
6 (85.7%) 
49 (90.7%) 
93 (91.2%) 
75 (96.2%) 
35 (89.7%) 
14 (100%) 
1 (14.3%) 
5 (9.26%) 
9 (8.8%) 
3 (3.9%) 
4 (10.3%) 
0 (0.00%) 
 
 
 
0.544 
Marital Status 
Married 
Single 
 
120(94.5%) 
128(94.1%) 
 
 
7 (5.5%) 
8 (5.9%) 
 
 
0.897 
Parity group 
No Children 
1-4 
5-8 
9+ 
 
3 (75.0%) 
34 (94.4%) 
134 (91.8%) 
58 (90.6%) 
 
1 (25.0%) 
2 (5.6%) 
12 (8.2%) 
6 (9.4%) 
 
 
0.594 
HIV status 
Negative 
Positive 
 
217 (93.9%) 
60 (84.5%) 
 
14 (6.1%) 
11 (15.5%) 
 
0.012
§
 
CD4 Count group 
≤ 200 
>200 
 
16 (84.2%) 
42 (85.7%) 
 
3 (15.8%) 
7 (14.3%) 
 
0.875 
Province 
Gauteng 
North West 
 
255 (91.7%) 
26 (89.7%) 
 
23 (8.3%) 
3 (10.3%) 
 
0.703 
 
The relationship between demographic factors with crude mortality was determined using chi 
squared test. Factors which had a p-value < 0.2 were considered to have a significant 
relationship with crude mortality. Only HIV status (p-value 0.012) had a statistically 
significant relationship with mortality. As a proportion HIV positive patients died more in 
comparison to HIV negative patients.  
 
                                                             
‡
p-value from chi squared test for categorical variables 
§ Statistically significant 
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Table 4.5: Clinical presentation and treatment modality factors associated with crude 
mortality 
Variable Mortality = 0 
(Alive) N=282 
Mortality= 1 
(Dead)  N=26 
p-value 
Type of Cancer 
Adeno Carcinoma 
SCC 
 
26 (89.7%) 
247 (91.8%) 
 
3 (10.3%) 
22 (8.2%) 
 
 
0.689 
Cancer Stage at Treatment 
Stage I 
Stage II 
Stage III 
Stage IV 
 
45 (95.7%) 
150 (95.5%) 
81 (84.4%) 
5 (71.4) 
 
2 (4.3%) 
7 (4.5%) 
15 (15.6%) 
2 (28.6%) 
 
 
0.002

 
EBRT Completed 
No 
Yes 
 
24 (70.6%) 
257 (94.1%) 
 
10 (29.4%) 
16 (5.9%) 
 
0.001
 
Brachytherapy Completed 
No 
Yes 
 
7(35.0%) 
266 (96.0%) 
 
13 (65.0%) 
11 (4.0%) 
 
0.001
 
Chemotherapy Prescribed 
No 
Yes 
 
101 (86.3 %) 
172 (95.0%) 
 
16 (13.7%) 
9 (5.0%) 
 
0.008

 
Total Followup Completed 
< 6 months 
6 - 12 months 
12 – 18 months 
18 – 24 months 
 
0 (0%) 
0 (0%) 
0 (0%) 
281 (99.6%) 
 
13 (100.0%) 
9(100.0%) 
3(100.0%) 
1(0.4%) 
 
 
 
 
0.001
 
Treatment Modality 
EBRT Only 
EBRT + Brachytherapy 
EBRT+Brachy+Chemotherapy 
 
8 (80.0%) 
101 (87.0%) 
172 (95.0%) 
 
2 (20.0%) 
15 (13.0%) 
9 (5.0%) 
 
 
0.023

 
Treatment Duration Days  
≤ 60 
>60 
 
275 (92.0%) 
6 (75.0%) 
 
24 (8.0%) 
2 (25.0%) 
 
0.089
 
Waiting Period 
0- 6 months 
6-12 months 
>12 months 
 
209 (92.9%) 
48 (92.3%) 
15 (88.3%) 
 
16 (7.1%) 
4 (7.7%) 
2 (11.8%) 
 
 
0.779 
Table 4.5 shows the relationship of clinical factors and treatment modality factors with crude 
mortality. 
                                                             
 Significant p - value 
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All variables were categorical and chi squared test was performed. From the above table, it 
can be concluded that, patients who had at least 18 months or more follow up post treatment 
were most likely to survive and attain 24 months overall survival, however, patients who had 
less than 18 months follow up period died within that same period.  Completion of prescribed 
EBRT, completion of prescribed brachytherapy and completion of treatment within 60 days 
also showed a significant association with mortality.  
 
4.2 Inferential Statistics 
4.2.1 Overall Survival and Mortality 
These patients contributed in total 576 person years by the end of the study period.  The 
incidence of mortality for the entire follow up period was 45 per 1000 person years (95% CI 
30.7 – 66.3).  Results of the period incidence rates of mortality at specific time points are 
summarised in Table 4.6 below. 
 
Table 4.6: Period incidence rates of mortality at specified time points per 1000 person years 
Period (years) Person-time 
(years) 
Failures Mortality 
Rate 
95% CI 
0 - 0.5 year 148.4 13 87.6 50.8 - 150.9 
0.5 - 1 year 145.1 9 62.0 32.3 - 119.2 
1 - 1.5 years 141.7 3 21.2 65.6 
1.5 - 2 years 141.0 1 7.1 50.3 
Total 576.3 26 45.1 30.7 - 66.3 
 
The overall 2 year mortality rate was 45.1 per 1000 person years.   During period 0 – 0.5 
year, the incidence mortality rate was the highest 87.6 per 1000 person years (95% CI 50.8 – 
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150.9).  The incidence rate decreased to 62.0 per 1000 person years (95% CI 32.3 - 119.2) 
during the period 0.5- 1 year, 21.2 per 1000 person years in the 1-1.5 years reaching a low of 
7.1 per 1000 person years during 1.5 - 2 years. The majority of patients died within the first 6 
months of follow up.  Also the number of patients followed up over 2 years decreased every 
year. 
 
Survival analysis is one of the tools used to assess the success of treatment. In this study, 
Kaplan Meier curve was used to determine the overall 2 years survival. Figure 4.1 shows the 
overall survival of patients during the study period. 
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Figure 4.1: Kaplan Meier curve of the 2 years overall survival  
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4.2.2 Predictors of survival 
Figures 4.2 - 4.7 below show the Kaplan Meier curves with significant logrank test. This was 
done to test the effect of different variables on overall survival. From Kaplan Meier curves, 
the null hypothesis, Ho: no overall difference between the survival curves was tested using a 
non-parametic logrank test. When the p-value is significant (p<0.2) it indicates that the null 
hypothesis should be rejected.  Therefore, we can conclude that there was a significant 
difference in the KM survival curves between the different groups 
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Figure 4.2: Kaplan Meier overall survival curve by cancer stage at treatment 
Early stage I and stage II patients had better survival as compared to late stages III and IV.  
This difference was significant (p-value: 0.023)  
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Figure 4.3: Kaplan Meier curve showing overall survival by HIV status 
HIV negative patients had better survival compared to HIV positive patients.  This difference 
was significant (p-value: 0.012) 
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Figure 4.4: Kaplam Meier overall survival curve by treatment modality 
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Patients who were treated with a combination of EBRT, brachytherapy and chemotherapy 
had better survival compared to those who just received EBRT only. This difference was 
significant (p-value: 0.024) 
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Figure 4.5: Kaplan Meier curve showing the effect of EBRT completion on overall survival 
Patients who completed the prescribed EBRT had better survival compared to those who 
didn’t. This difference was significant (p-value <0.001) 
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Figure 4.6: Kaplan Meier curve showing the effect of brachytherapy treatment on overall 
survival 
Patients who completed the prescribed brachytherapy had better survival compared to those 
who didn’t complete treatment. This difference was significant (p-value < 0.001) 
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Figure 4.7: Kaplan Meier curve showing the effect of chemotherapy treatment on overall 
survival  
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Patients who received chemotherapy had better survival compared to those who didn’t 
receive it. This difference was significant (p-value: 0.083) 
This significant difference in KM survival curves between different groups was also seen for 
CompletedFollowup and Treatmentduration days.  
 
The equality of survival curves was tested using logrank test. These results are shown in 
Table 4.7 below. From the results, a p-value <0.2 was considered significant.  
Table 4.7: Logrank test of equality of survival functions 
 Log-rank  Chi square p-value 
Age group 3.92 0.562 
HIV status 6.38 0.012
* 
CD4count group 0.05 0.818 
Cancer Stage at Treatment  14.50 0.023
* 
Treatment Modality 7.47 0.024
* 
Chemotherapy Prescribed 6.98 0.083
* 
EBRTCompleted 24.94 0.001
* 
BrachyCompleted 143.66 0.001
* 
Treatment Duration days 3.32 0.0685
* 
WaitingPeriod  0.44 0.801 
Province 0.11 0.735 
*
:significant  p-value <0.2 
 
Table 4.8 below shows the results of the univariate analysis. To identify the predictors of 
survival of cervical cancer and potential prognostic factors, Cox proportional hazards model 
was fitted starting with univariate analysis. The proportional hazard assumption was also 
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tested using Schoenfeld residuals and variables which showed violation of this assumption 
were not included in the final model. From the univariate analysis variables which were 
found significant at 0.2 percent level were added into a multivariate model, starting with the 
most significant variable.  Also variables which were found to be significant prognostic 
factors of cervical cancer from previous studies were forced into the model. 
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Table 4.8: Cox proportional hazards univariate analysis  
Variable Hazard Ratio 95% CI p-value 
EBRT Completed 
No 
Yes  
 
Ref 
0.17 
 
 
0.08 – 0.37 
 
 
0.001
** 
Brachytherapy Completed 
No 
Yes 
 
Ref
* 
0.037 
 
 
0.02 – 0.08 
 
 
0.001
**
 
HIV status 
Negative 
Positive 
 
Ref* 
2.66 
 
 
1.21 – 5.86 
 
 
0.015
** 
Treatment Duration Days 
<=60 
>60 
 
Ref* 
3.51 
 
 
0.83 – 14.9 
 
 
0.088
**
 
Chemo 
No 
Yes 
 
Ref* 
0.35 
 
 
0.15 – 0.79 
 
 
0.012
** 
Stage at treatment 
Stage I 
Stage II 
Stage III  
Stage IV 
 
Ref* 
1.04 
3.88 
7.12 
 
 
0.22 – 5.01 
0.89 – 17.0 
1.01 – 51.0 
 
 
0.960 
0.072 
0.049 
Treatment Modality 
EBRT Only 
EBRT + Brachytherapy 
EBRT+ Brachytherapy 
+Chemotherapy 
 
Ref* 
0.65 
0.24 
 
 
0.15 – 2.83 
0.05 – 1.11 
 
 
0.562 
0.067 
Province 
Gauteng 
Northwest 
 
Ref* 
1.23 
 
 
0.37 – 4.10 
 
 
0.735 
CD4 Count group 
<=200 
>200 
 
Ref* 
0.85 
 
 
0.22 – 3.30 
 
 
0.818 
Waiting Period 
0- 6 months 
6-12 months 
12+ months 
 
Ref* 
1.10 
1.63 
 
 
0.37 – 3.30 
0.38 – 7.11 
 
 
0.864 
0.512 
Age (years) 0.98 0.94 – 1.01 0.220
 
**
 
                                                             
**
 Significant p-value 
* Ref – the first group used as a reference in STATA 
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The following factors were found to be significant predictors of survival in the univariate 
analysis: EBRT completed, brachytherapy completed and chemotherapy prescribed. HIV 
status and treatment duration days also proved to be significant prognostic factors. These 
factors were then tested for proportional hazard assumptions and showed no evidence of 
violating the proportional hazard assumption.   
 
In the univariate analysis, patients who completed EBRT and brachytherapy treatment had 
83% and 96% respectively less risk of dying compared to those who did not complete their 
treatment. Patients who had in addition chemotherapy prescribed, had 65% less risk/chance 
of dying compared to those who did not receive chemotherapy.  HIV positive patients were 
2.66 times more likely to die as compared to those who were HIV negative. Patients who 
took over 60 days to complete treatment were 3.5 times more likely to die compared to those 
who completed treatment within 60 days.   Cancer stage at treatment, completion of follow 
up, treatment modality, province, CD4 Count, waiting period and age were not associated 
with mortality in the univariate analysis. 
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Table 4.9 below shows the results of the multivariate analysis. Factors which were significant 
at 5% level were considered to be potential predictors and prognostic factors of cervical 
cancer. 
Table 4.9: Cox proportional hazard multivariate analysis 
Variables Hazard Ratio 95% CI p-value 
Age 0.98 0.93-1.04 0.573 
EBRT Completed 
No 
Yes  
 
Ref 
0.48 
 
 
0.16-1.47 
 
0.199 
Brachytherapy Completed  
No 
Yes 
 
Ref 
0.04 
 
 
0.01-0.11 
 
0.001
* 
HIV status 
Negative 
Positive 
 
Ref 
3.23 
 
 
1.04-10.0 
 
0.042
* 
Chemo 
No 
Yes 
 
Ref 
0.83 
 
 
0.24-2.91 
 
0.775 
Treatment Duration Days 
<= 60 days 
>60 days 
 
Ref 
2.67 
 
 
0.51-14.0 
 
0.246 
*
p<0.05 
 
In the multivariate analysis completion of brachytherapy remained significant predictor of 
survival after adjusting for all other factors.  HIV status was the only significant prognostic 
factor. Patients who completed brachytherapy treatment were 96% less likely to die 
compared to those who didn’t complete it at any point in time, after adjusting for age and 
HIV status.  Patients who were HIV positive were 3.2 times more likely to die as compared to 
HIV negative patients at any point in time after adjusting for age and brachytherapy 
completed.  The final model didn’t show any violation of the proportional hazard assumption, 
global test p-value = 0.614 
The results of the global tests for proportional hazard assumptions based on Schoenfeld 
residuals are shown in Table 4.10 below. 
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Table 4.10: Proportionality hazard assumption test 
Variables PH assumption p-value 
EBRT Completed 0.408 
Brachy Completed  0.217 
Completed FollowUp 1.000 
Treatment Duration Days 0.490 
HIV status 0.934 
Chemotherapy Prescribed 0.962 
Age 0.678 
Cancer Stage at Treatment  0.630 
Treatment Modality 0.617 
Province 0.057 
CD4 Count  0.068 
Waiting Period  0.178 
 
Table 4.10 above shows the p-values from the global test of the proportional hazard 
assumption. When p>0.05 then the assumption is not violated. 
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CHAPTER FIVE 
DISCUSSION 
 
This study investigated the several prognostic factors of cervical cancer patients undergoing 
radiotherapy at CMJAH and the overall survival rates of this patient population. Results of 
this work add to the local knowledge of the epidemiology and statistics of cervical cancer 
patients undergoing radiotherapy in a typical public university teaching hospital. In the 
paragraphs that follow the results of this work are discussed in the context of the present 
literature and public health service delivery in South Africa.  
 
5.1 Overall survival rate 
This study established that the 2-year overall survival rate was 92 % for this patient 
population. This high survival rate can be attributed to the high loss to follow-up. In a 
developing country loss to follow-up is typically high for various reasons, ranging from 
financial implications of travelling to the radiotherapy centre, lack of understanding of its 
importance and doctor-patient encounter being non-meaningful post treatment. Incentives can 
be introduced to make patients honour their follow-up appointments (incentives can be in the 
form of bus fare). Follow-up statistics can be possibly be improved by having the follow-up 
visits done at local clinics by trained nurses and the results faxed to the attending radiation 
oncologist for review.  A national health insurance system is envisaged to be an ideal 
platform for easier sharing of patient data across the country. The overall 2 year mortality rate 
was calculated to be 45 per 1000 person years. It is of interest that in this present data set 
patient deaths occurred in the first 18 months, which implies that follow-up is critical in the 
first 24 months post radiotherapy.   
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5.2 Potential prognostic factors 
This study investigated the potential prognostic factors for cervical cancer patients presenting 
for radiotherapy at CMJAH. Below some pertinent results of the various potential prognostic 
factors tested are discussed: 
 
In this study patient age, HIV status, treatment duration, administration of chemotherapy 
drugs, completion of external beam radiotherapy and completion of brachytherapy were 
found to be significant predictors of mortality in the univariate cox regression model. These 
findings are in agreement with the work of other researchers.   However, further subjection of 
the same predictors to multivariate Cox regression model showed that only HIV status and 
completion of brachytherapy remained significant after adjusting for all other factors.  
Furthermore, these two factors didn’t show signs of violating the proportional hazard 
assumption.  
Age 
There has been a lot of controversy surrounding age, whether its a prognostic factor for 
cervical cancer or not.  In this study, KM survival curves showed that patients who were less 
than 30 years of age had the worst survival, in contrast Geetha et al found that younger  
patients (less than or equal to 30 years) had longer post treatment survival.  However, the 
results in this study were similar to that of Kastritis et al where they observed younger 
patients (less than 35 years) to have worst survival post treatment. In this study, 85% of the 
patients in the less than 30 years group were HIV positive this might have led to their 
survival being low. This further show that there could be a link between HIV and cervical 
cancer therefore studies have to be done to investigate this possibility. Also in this study, 
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patients above 70 years had a better survival although this difference was not statistically 
significant. This is similar to findings by Geetha et al who found that older patients above age 
70 had longer post treatment survival. In contrast to what has been widely reported in 
literature that patients above 50 years are the ones with a high risk of cervical cancer, this 
study population showed that it was indeed patients less than 30 years having a greater 
chance of having cervical cancer. It deserves mentioning that this age group of less than 30 
years had a high proportion of HIV positive patients. The current national health policy on 
cervical cancer screening targets women at least 30 years old, which means significant 
number of cervical cancer cases are being missed in the population aged less than 30 years. It 
was found that the peak age group of this population was 40-49 years which is alarming as 
this age group is the countries’ productive work force hence efforts of prevention of the 
disease have to be put forward to protect this population for the countries’ benefit.  
HIV 
In this study, from the Kaplan Meier survival curves HIV positive women had poorer 
survival as compared to HIV negative women. This also remained only significant prognostic 
factor in the multivariate analysis. Poor survival rates in HIV positive women have been 
observed elsewhere, for example in studies by Kigula-Mugambe and Kavuma and by 
Maiman et al.  With HIV pandemic in Africa, this shows further motivation to increase 
screening coverage directed at HIV positive women who are also at more risk of cervical 
cancer due to high infection of HPV which has been found to be a risk factor for cervical 
cancer.  Also because of the increased access of ARV treatment, the lifespan of people living 
with HIV has increased therefore putting them at more risk of developing cancer.  This study 
also showed that HIV positive women presented more with late stage II and III, which 
emphasises the need for early detection of these abnormal lesions in order to prevent new 
cases of cervical cancer also to have better treatment outcome. Another aspect which needs to 
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be looked at in future is the response of HIV positive patients on ARVs compared to those 
who were not yet on ARVs. 
Stage at Treatment  
Presentation of patients with advanced cancer is a consistent feature in most studies done in 
the developing world. This study showed that a large number of patients at CMJHA 
presented with late stages with 51%, 31% and 2% in stage II, stage III and stage IV 
respectively. Late presentation by patients might be due to lack of dedicated and effective 
screening programmes within the government policy, lack of HPV vaccines and its high costs 
and also lack of access and knowledge of such services by patients.   However, in general 
these results confirm that patients with higher clinical stage have poor prognosis as compared 
to those with early stage.  From the univariate analysis, stage III and stage IV patients had 
higher risk of dying from cervical cancer compared to stage I and stage II patients. These 
findings are in agreement with a study done by Hopkins and Morley. This can be because at 
stage III and IV the disease would have spread to other areas of the body making it more 
difficult to treat and control.   
Treatment Modality 
Cancer management in most cases involves multi-therapies and in most cases the choice of 
the therapy given to a patient influences treatment outcomes and eventually survival of the 
patient. For example a study by William et al showed that a combination of radiation therapy 
and chemotherapy had superior survival rates compared to radiation therapy alone on cervical 
cancer patients (81 % for radiation therapy in combination with chemotherapy vs 71 % for 
radiation therapy alone). Despite there being evidence of superior treatment outcomes for 
combined radiotherapy and chemotherapy some of the patients in this study did not receive or 
benefit from chemotherapy. These were patients who where HIV positive and had a CD4 
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count of less than 200, this is because this patient group generally cannot tolerate toxic 
chemotherapy drugs and would develop severe side effects on patients. This study 
underscores the effectiveness of combined therapy (external radiation beam therapy, 
chemotherapy and brachytherapy) in the management of cervical cancer. 
Treatment Duration 
Tumour control is affected by the timing of the diagnosis, treatment commencement and 
length of the therapy intervention. This is mainly because the cancer cells will continue to 
grow and multiply, the more these cells grow the more difficult it will be to kill them as they 
may spread to other surrounding area. Thus it is important to finish the treatment without any 
gaps in between and also within a short space of time. This study showed that patients who 
completed their treatment within 60 days had a better survival compared to those who took 
over 60 days to complete treatment.  In the univariate analysis those who took longer to 
complete treatment were four times more at risk of dying.  Thus emphasis should be put on 
educating patients about the importance of not absconding during the treatment.  These 
results are similar to a study done by Fyles where he found that there was 1% loss of disease 
control per day of treatment prolonged beyond 30 days. A number of patients in this 
retrospective analysis did not comply with the treatment schedule, skipping treatments in 
between thus prolonging their treatment duration which has potential to compromise tumour 
control. It is therefore important for patients to be encouraged and shown the importance of 
completing the treatment within the prescribed time. Provision of lodging facilities outside 
the normal ward set-up should be explored as an alternative to patients travelling from home, 
which should potentially get rid of skipping of treatment due to lack of transport. 
Since disease control is affected by timing of treatment commencement, it is important to 
ensure that the waiting period between diagnosis and the start of treatment is not too long.  
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This might be difficult to achieve in settings where radiotherapy centers are limited or not 
available in the developing world hence increasing mortality due to untreated cervical cancer.  
In this study, patients who had more than 6 months waiting period had less survival as 
compared to those with less waiting period. Patients whose waiting period was 12 months or 
more had 63% more risk of dying than those who had less than 6 months waiting but these 
results were not significant. Furthermore machine breakdowns compromise patient care as it 
extends the treatment period to an extent that the therapy intent is negated by the tumour 
kinetics. Public health administrators should be encouraged to pay the vendors who supply 
and repair radiotherapy equipment in time such that they continue providing service. In recent 
years it has been widely reported in media where public hospital radiotherapy services are not 
available due to non-payment of private service providers. 
Histology type 
Squamous cell carcinoma has been the leading type of histology in most studies and in the 
present one. In this study, 88% of the patients had squamous cell carcinoma compared to only 
9% with adenocarcinoma. Similar findings have been reported in a Thailand study by Pomros 
et al. This is in agreement with this study finding where squamous cell carcinoma had a better 
survival compared to adenocarcinoma. This type of cancer has good response to radiotherapy 
as compared to adenocarcinoma and therefore a favourable prognostic factor. 
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5.3 Limitations 
This research work had some limitations which have to be considered when interpreting the 
results. For example the significant proportion of patients lost to follow-up should be taken 
into account when interpreting the survival rates.  In this study 66% of patients who were 
treated during the study period were lost to follow up. A number of possibilities can be put 
forward to explain this significant loss to follow up, for example, a large proportion of the 
patients presented with late stage tumors which possibly meant early mortality after 
treatment. As shown from the study demographics, CMJAH served patients outside the 
Johannesburg metropolitan area meaning the majority of the patients had to travel long 
distances to the hospital, which can be daunting in terms of the finance aspects especially for 
the low income and pension groups. This significant proportion of patients lost to follow up 
weakens the statistical power of the study; however the challenges of cancer treatment in a 
typical public hospital in South Africa have been exposed by this study. Therefore a 
cautionary approach is recommended in interpreting the survival rates.  
This significant number of patients lost to follow up also brings with it bias to this study, 
which needs acknowledging for proper conclusions to be drawn from this study. The concept 
of censoring assumes that censored patients have the same survival prospects or prognosis as 
those who remained in the study and completed follow up. This may not always be true, as 
some of these patients feel fully recovered after receiving treatment and thus deem it not 
necessary to return for follow up. On the other hand, some these patients either have poor 
treatment outcomes or succumb to illness and die.  In both cases, censoring brings 
unavoidable bias into the study which needs to be taken into context when conclusions or 
inferences are drawn from the study.   In this study overall survival was based on those 
patients who completed follow up, meaning either the  survival rate was  overestimated if 
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those lost to follow up had died or  underestimated if those lost to follow up were still alive, a 
limitation which this study acknowledges. 
 
Another limitation to this study was that all patient deaths were attributed to cervical cancer 
which is not always the case in a clinical setting. During the period under review a total of 
2212 patients had histologically confirmed cervical cancer, however only 900 had complete 
treatment data records although not all of them were eligible for the study. The ineligibility of 
the other two-thirds of the patient population reduces the statistical power of this work. It 
needs mentioning that the ineligibility of most patients was due to lack of recorded treatment 
data: see Chapter Six for recommendations to alleviate this problem.  
 
A significant proportion of the cervical cancer patient population who was treated at CMJAH 
which were not eligible for this study was mainly due to lack of proper recording of patient – 
or treatment related data. Out of a total patient population of 2212 during the study period, a 
significant 1092 patients had missing treatment data thus making them ineligible for the 
study.  A number of reasons can be postulated for this, for example, some of these patients 
could be referrals from the private health sector thus there was no need for comprehensive 
data collection and recording into the CMJAH filing system as the patients data is already 
captured into their private health clinic filing system or due to simple poor data capture by the 
clerical staff at CMJAH. 
This research work exposed some fascinating facts about the demographics of cervical cancer 
patients presenting at CMJAH for radiotherapy treatment. This work showed that the 
radiotherapy patient catchment area went beyond the borders of Gauteng Province. In this 
study 91% patients came from Gauteng Province and 9% from North West Province. From 
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1092 patients excluded in the study, about 50% of that was from Botswana (private sector/ 
Netcare) and about 5% from Zambia and Zimbabwe. In 2010 the North West Province started 
providing radiotherapy services at Klerksdorp Hospital as such the numbers from North West 
Province are no longer presenting. In recent years International Atomic Energy Agency 
(IAEA) funded projects to equip neighbouring countries with radiotherapy equipment should 
lead to no patients presenting from outside the South African boarders. 
 
In this study all patient deaths were attributed to cervical cancer which is not necessarily true. 
It is not a trivial task to establish the cause of a patient’s death as that can only be established 
through the access to the patient’s death certificate. The current practice does not capture the 
patient’s national identity number thus making it impossible to trace the cause of death 
through the Department of Home Affairs database. The impact of surgery was not 
investigated in this present study despite some of the patients having benefited from it.  
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CHAPTER SIX 
RECOMMENDATIONS AND FUTURE STUDIES 
 
6.1 Recommendations and Future Studies 
A number of recommendations are hereby put forward based on the practical experience of 
this research work. 
1. The long treatment waiting period experienced by public hospital cancer radiotherapy 
patients in general motivates for additional radiotherapy centres be available within 
Gauteng province in order to reduce the long waiting period and possible lead to 
better treatment outcomes.   
2. Teaching of patients in understanding the benefit of adhering and completing the 
treatment within the prescribed time as well as encouraging patients to present for 
follow-up post treatment. The financial implication of travelling for an average of 
four weeks for radiotherapy treatment is acknowledged in a developing country, thus 
government and non-governmental organisations interventions to assist deserving 
patients with travel costs would be welcome. Most countries in the world house their 
cancer patients in government funded lodgings during their treatment.  
3. Since most patients in this study died in the first 2 years post treatment it is 
recommended that patients present for follow up every three months in the first two 
years after treatment as opposed to the present six months interval. 
4. Continued community based education and awareness of the risk factors and 
prevention of cervical cancer, this can reduce the burden of patients needing 
radiotherapy treatment which is can cut costs in the health system. 
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5. HIV positive women to be screened more regularly in order to prevent late 
presentation with cervical cancer. 
6. For more meaningful analysis of survival data it is recommended that all radiotherapy 
patients have their national identity numbers recorded in addition to their 
“radiotherapy centre treatment numbers” such that it could be possible to link the 
data between the national mortality database and hospital database. 
7. Training of personnel on the importance of correct an accurate record keeping of 
patients for future studies. Quality control measures can be easily implemented to 
ensure that clerical staff enter and record all the necessary patient treatment specific 
data. Moving away from paper forms to digital forms can help in ensuring that all data 
is captured by employing software programs which won’t save the form without all 
pre-requisite information. 
 
From a public health scientist’s perspective there was a lot learnt from this study about 
radiotherapy treatment of cervical cancer, however, there still remains some local knowledge 
gaps and thus some aspects deserve to be explored further in future studies in order to have a 
sustainable cost-effective public service radiotherapy delivery service. Below are some 
suggestions for future work: 
1. A study designed to link survival rate to quality of life and cause of death would be 
appropriate and more informative to health practitioners and policy makers. 
2. The long waiting periods can be shortened by conducting of peer-reviewed 
prospective hypofractionation clinical trials.  
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3. Studies to identify prognostic factors should be extended to other cancer sites with the 
aim of cost-effective healthcare delivery. 
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CHAPTER 7 
CONCLUSIONS 
7.1 Conclusions 
This present retrospective study involved 307 cervical cancer patients treated during the 
period 1 January 2004 to 31 December 2006 at CMJAH and met the inclusion criteria. From 
this study the 2 year overall survival rate of cervical cancer patients was 92%. Based on this 
study, only HIV status was found to be a statistically significant prognostic factor (p-value 
=0.04), while completion of the brachytherapy prescription proved to be a significant 
predictor of mortality (p-value < 0.001). Nearly 66% of the eligible patients in the study were 
lost to follow-up, therefore results of this study have to be interpreted bearing this in mind. 
The statistics from this study further reinforces the importance of screening in the fight 
against cervical cancer. It is recommended that prospective clinical trials be conducted in the 
future to confirm the validity of the findings of this work. This study has successfully 
contributed to the local body of knowledge with regards to treatment of cervical cancer in 
typical a public teaching hospital in South Africa. 
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